A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante  ¹     Valerie Pivorunas  ²     James Butler  ³     Naim Mahi  ³     Nael M. Mostafa  ³     Melanie Ruzek  ²     James Fann  ²     Feng Hong  ⁴     Xiaohong Cao     Nizar Smaoui     Justin Wade Davis     Jasmina Kalabic     Alexandra Song     Heath M. Guay     Florian Rieder     Julian Panés     Jean-Frédéric Colombel    
¹ University Hospitals Leuven,KU Leuven,Belgium
² AbbVie Bioresearch Center,Worcester,United States
³ AbbVie Inc.,North Chicago,United States
⁴ AbbVie Bior

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)